【结 构 式】 |
【药物名称】CGP-29861 【化学名称】3-Formylrifamycin SV hydrazone with 2-amino-7-ethylperhydro-1H-pyrido[1,2-a]pyrazine 【CA登记号】100070-82-4 【 分 子 式 】C48H66N4O12 【 分 子 量 】891.08082 |
【开发单位】Novartis (Originator) 【药理作用】Rifamycins |
合成路线1
The cyclization of 5-ethylpiperidine-2-carboxylic acid ethyl ester (I) with aziridine (II) in ethanol gives 7-ethylperhydropyrido[1,2-a]pyrazin-1-one (III), which is reduced with LiAlH4 to yield 7-ethylperhydropyrido[1,2-a]pyrazine (IV). The reaction of (IV) with NaNO2/HCl, followed by reduction with LiAlH4, affords 7-ethylperhydropyrido[1,2-a]pyrazin-2-amine (V), which is finally condensed with rifamicin SV-3-carbaldehyde (VI).
【1】 Hauffe, S.; Tosch, W.; Batt, E.; Ashtekar, D.R.; Costa-Pereira, R.; Vischer, W.; Traxler, P.; Degen, P.; Zak, O.; Imhof, P.; Gowrishankar, R.; 3-Formylrifamycin SV-hydrazones with diazabicycloalkyl side-chains: New rifamycins aganist tuberculosis with long plasma half-lives. 27th Intersci Conf Antimicrob Agents Chemother 1987, Abst 278. |
【2】 Traxler, P. (Novartis Corp.); Novel polycyclic hydrazones of rifamycins, their manufacture, and their pharmaceutical compsns. for treating tuberculosis. US 4681938 . |
【3】 Traxler, P.; Vischer, W.; Zak, O.; New Rifamycins. Drugs Fut 1988, 13, 9, 845. |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(I) | 43688 | ethyl 5-ethyl-2-piperidinecarboxylate | C10H19NO2 | 详情 | 详情 | |
(II) | 10151 | Ethyleneimine; Aziridine; Azirane | 151-56-4 | C2H5N | 详情 | 详情 |
(III) | 43689 | 7-ethylhexahydro-2H-pyrido[1,2-a]pyrazin-1(6H)-one | C10H18N2O | 详情 | 详情 | |
(IV) | 43690 | 7-ethyloctahydro-2H-pyrido[1,2-a]pyrazine | C10H20N2 | 详情 | 详情 | |
(V) | 43691 | 7-ethyloctahydro-2H-pyrido[1,2-a]pyrazin-2-amine; 7-ethyloctahydro-2H-pyrido[1,2-a]pyrazin-2-ylamine | C10H21N3 | 详情 | 详情 | |
(VI) | 43692 | 26-formyl-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1(4,7).0(5,28)]triaconta-1(28),1(29),2,4,9,19,21,25,27-nonaen-13-yl acetate | C38H47NO13 | 详情 | 详情 |